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S U M M A R Y
Objectives: The aims of this study were to investigate the effect of hepatitis B virus (HBV) replication on
the metastatic ability of hepatocellular carcinoma (HCC) cells and to explore a potential mechanism from
the perspective of epithelial–mesenchymal transition (EMT).
Methods: Two short-interfering RNAs (siRNAs) against the HBV S gene were used to inhibit HBV
replication in HepG2.2.15 cells. To evaluate the level of HBV replication and interference efﬁciency, HBV
antigen and HBV DNA were detected by ELISA and quantitative PCR (Q-PCR). Invasion and metastatic
abilities were compared between different groups by wound healing and trans-well assays.
Immunoﬂuorescent staining and Western blotting were utilized to detect EMT markers.
Results: Both siRNAs effectively inhibited HBV replication in HepG2.2.15 cells. Compared to control
HepG2.2.15 cells, cells transfected with the siRNAs showed characteristics of the mesenchymal
phenotype and augmented their ability to invade and metastasize. Inhibition of HBV replication
suppressed E-cadherin and induced a switch to vimentin expression. Western blots conﬁrmed the
decrease in E-cadherin expression. The level of E-cadherin expression was also lower in HepG2 cells than
in HepG2.2.15 cells.
Conclusions: siRNAs were able to effectively inhibit HBV replication in vitro. A high load of HBV
replication may inhibit the invasion and metastatic ability of HCC cells by reversing the EMT process.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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Hepatocellular carcinoma (HCC) is the ﬁfth most common
malignancy and third leading cause of cancer-related death in the
world.1 A high potential for vascular invasion and metastasis of
HCC is associated with a poor prognosis.2 Hepatitis B virus (HBV)* Corresponding authors.
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http://dx.doi.org/10.1016/j.ijid.2013.11.015infection is the most important risk factor for HCC and is present in
approximately 80% of HCC patients.
It has been reported that metastasis and recurrence is more
common in HCC patients with an HBV infection than in those
without.3,4 HBV DNA integration, especially the HBV X gene, is
regarded to be critical for these processes.5,6 However, our
previous studies have found that HepG2.2.15 cells that are
transfected with HBV whole genome and support stable HBV
replication, show decreased proliferation and metastatic ability
compared to parental HepG2 cells.7,8 Qiu et al. reported that HBV
infection decreases the risk of liver metastasis in patients with
colorectal cancer and elevates the surgical resection rate of liver
metastases.9 Zhou et al. found that the outcome of intrahepatic
cholangiocarcinoma (ICC) patients with HBV infection is better
than the outcome of patients without HBV infection after curative
resection,10 though HBV infection is an independent risk factor forociety for Infectious Diseases. Open access under CC BY-NC-SA license.
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mechanisms is contradictory and remains unclear.
It is possible that the effect that HBV elicits in cells depends on
its state. A high load of HBV replication may inhibit the metastatic
ability of the host cell, while integration of only a part of the HBV
gene into the host cell may lead to increased metastatic ability. In
this study, a short-interfering RNA (siRNA) approach was used to
inhibit HBV replication in HepG2.2.15 cells, and the metastatic
ability of these cells was examined in comparison to HepG2.2.15
cells. Furthermore, the potential mechanism was explored from
the perspective of epithelial–mesenchymal transition (EMT).
2. Methods
2.1. Cell line and cell culture
The HepG2.2.15 cell line supports stable HBV replication and
protein expression, as well as the production of virus particles.12
The cells were cultured in Dulbecco’s modiﬁed Eagle medium
(DMEM; Hyclone, Logan, UT, USA) supplemented with 10% fetal
bovine serum (FBS; Invitrogen, Carlsbad, CA, USA), 100 mg/ml
streptomycin, 100 IU/ml penicillin, and 380 mg/ml G418 (Invitro-
gen) at 37 8C in a 5% CO2 incubator.
2.2. siRNA and transfection
Two siRNAs were designed against the HBV S gene (GenBank
accession number U95551.1); they were synthesized and puriﬁed
by Invitrogen Co. (Shanghai, China). Their sequences are as follows:
siRNA1 sense-GCGGGUAUAU UAUAUAAGATT, antisense-UCUUAUA
UAAUAUACCCGCTT; siRNA2 sense-GGGACUUC AAUCCCAACAATT,
antisense-UUGUUGGGAUUGAAGUCCCTT. The negative control
(NC) was a scrambled sequence without any signiﬁcance.
Transfection was performed using Lipofectamine 2000 (Invi-
trogen) in accordance with the manufacturer’s instructions.
HepG2.2.15 cells were seeded in 24-well plates with 5  104 cells
per well, 1 day before transfection. The ﬁnal concentration of siRNA
was 20 nmol/l.
2.3. ELISA and Q-PCR
The HBV e antigen (HBeAg) in culture medium, which can
reﬂect the level of HBV replication, was examined by ELISA (Intec,
Xiamen, China). Meanwhile, the HBV DNA level in supernatant was
assayed by ﬂuorescence quantitative PCR (Q-PCR; PG Biotech,
Shenzhen, China). These processes were performed in accordance
with the manufacturer’s instructions. The results were used to
determine the level of HBV replication and the interference
efﬁciency of the siRNAs in HepG2.2.15 cells.
2.4. Wound healing assay
After 24 h of transfection, the cells were grown to conﬂuence
and wounds were introduced using a pipette tip. The plates were
washed twice with DMEM to remove detached cells and incubated
in complete growth medium without FBS. The width was
measured and photographs were taken immediately (0 h) and at
72 h after wounding. The recovery ability was represented as a
percentage of the initial width.
2.5. Trans-well assay
After 24 h of transfection, the cells were trypsinized for the
trans-well assay. In brief, complete medium (600 ml) was added
to the lower compartment of an invasion chamber, and 5  104
cells in 200 ml serum-free medium were added to the upperchamber. After 72 h of incubation, the migrated cells were ﬁxed
and stained with hematoxylin and eosin, and the number was
counted in ﬁve randomly selected power ﬁelds under light
microscopy.
2.6. Immunoﬂuorescent staining
After 72 h of transfection, the cells seeded on a coverslip were
ﬁxed with 10% formalin and permeabilized with 0.1% Triton X-100.
E-cadherin (CST, MA, USA) and vimentin (ZSGB-BIO, Beijing, China)
antibodies were incubated with the cells at 37 8C for 1 h.
Fluorescein-labeled anti-rabbit and Texas red-labeled anti-mouse
secondary antibodies (Vector, Burlingame, CA, USA) were used
against the respective primary antibodies. 40,6-Diamidino-2-
phenylindole (DAPI) was used to stain the nucleus.
2.7. Western blot analysis
After 72 h of transfection, the protein extracted from cells was
separated by sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) and transferred onto polyvinylidene diﬂuor-
ide (PVDF) membranes. The membranes were incubated with E-
cadherin antibody at a dilution of 1:800 overnight at 4 8C and
subsequently incubated with alkaline phosphatase (AP)-conjugat-
ed secondary antibodies (ZSGB-BIO) for 1 h at room temperature.
Immunoreactive bands were detected using Western Blue
(Promega, Madison, WI, USA). b-Actin (ZSGB-BIO) was used as
the internal control.
2.8. Statistical analysis
All data were presented as the mean  standard deviation. The
two groups were compared with the Student’s t-test. A p-value of
<0.05 was considered statistically signiﬁcant.
3. Results
3.1. Both siRNAs can inhibit HBV replication in HepG2.2.15 cells
As shown in Figure 1a, HBeAg was stably produced in
HepG2.2.15 and NC cells, while it was signiﬁcantly decreased in
the cells transfected with siRNA1 and siRNA2, by ELISA. The HBV
DNA was also distinctly reduced in siRNAs-treated cells compared
to HepG2.2.15 and NC cells by Q-PCR (Figure 1b). The two siRNAs
against the HBV S gene effectively inhibited HBV replication in
HepG2.2.15 cells, and there was no signiﬁcant difference between
their interference efﬁciency.
3.2. Decreased HBV replication induced cellular morphological
changes
Morphological features were characterized by inverted micro-
photography (Figure 2). HepG2.2.15 cells were oval and lacked
processes. They grew in multiple adherent layers and exhibited
epithelial phenotypes. However, HepG2.2.15 cells transfected with
siRNAs were relatively scattered and had extended processes,
which are characteristic of a mesenchymal phenotype. This
suggested that the cells transfected with siRNAs were relatively
invasive.
3.3. Inhibition of HBV replication augmented the metastatic ability of
HepG2.2.15 cells
The results of the wound-healing assay demonstrated an
augmented migration capacity in HepG2.2.15 cells transfected
with siRNAs when compared to the blank control and the NC group
Figure 1. Determination of the interference efﬁciency of the siRNAs. (a) Detection of
HBeAg by ELISA. The level of HBeAg in supernatant was signiﬁcantly decreased in
HepG2.2.15 cells transfected with siRNA1 and 2 compared to blank (HepG2.2.15)
and negative control (HepG2.2.15-NC) cells. (b) Detection of HBV DNA levels by Q-
PCR. The measured HBV DNA levels were normalized to the level of HepG2.2.15
cells at 24 h. The HBV DNA in supernatant was distinctly reduced in siRNA-treated
cells compared to HepG2.2.15 and NC cells. Compared to HepG2.2.15 cells,
*p < 0.01.
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than the siRNA1 group (p < 0.05), although both siRNAs presented
a similar interference efﬁciency in HepG2.2.15 cells. More cells
transfected with siRNAs migrated through the pores of the
membrane and entered the lower side of the invasion chamber
than in the control group (Figure 3c, d). Trans-well analysis
demonstrated that both siRNAs enhanced the invasive ability of
HepG2.2.15 cells. These results suggested that invasion and
metastasis was increased when HBV replication was inhibited
by HBV siRNAs in HepG2.2.15 cells.
3.4. E-cadherin was decreased after HBV replication inhibition by
siRNAs
According to the results of the immunoﬂuorescent staining, the
epithelial marker E-cadherin was highly expressed in HepG2.2.15
and NC cells, whereas the level of the mesenchymal marker
vimentin was low. The expression of both markers was reversed
when HBV replication was inhibited in HepG2.2.15 cells by either
siRNA (Figure 4). Meanwhile, the results of the Western blot assays
also conﬁrmed the higher level of E-cadherin expression in
HepG2.2.15 and NC cells compared to those transfected with
siRNA1 or 2 (Figure 5). Additionally, HepG2, which is the parental
cell line of HepG2.2.15 and has a relatively higher invasive
potential, also showed lower expression of E-cadherin.Figure 2. Morphological features of the different cellular subgroups. HepG2.2.15 cells t
blank control and negative control (NC) cells, which demonstrated a more epithelial p4. Discussion
Although signiﬁcant research has focused on the role of HBV in
HCC, the exact function and mechanism by which HBV functions
remains unclear. Most studies have focused on the effect of part
HBV gene integration into DNA of the host cell, whereas only a few
have investigated HBV whole genome integration or HBV
replication. This study primarily explored the relationship
between HBV replication and the invasive potential of the host
cells, based on our previous ﬁndings.
It has been indicated that RNA interference (RNAi) can inhibit
HBV replication effectively in cell culture and in vivo and is
believed to have therapeutic potential for HBV infection.13,14 A
number of studies have veriﬁed that speciﬁc siRNAs targeting four
open reading frames (ORFs) of HBV are efﬁcient at inhibiting the
expression of viral antigens and the replication of HBV DNA.15–18
Fu et al. designed and evaluated 23 siRNAs targeted throughout all
four ORFs of HBV. The results showed that most of them were
effective, but the siRNAs targeting different ORFs could lead to
different efﬁcacy in inhibiting HBV expression and replication.19 It
has been found that the joint use of siRNAs can provide a more
powerful tool for the treatment of viral infection.20 The therapeutic
potential of siRNAs should be explored further. In this study, two
siRNAs were designed and synthesized against the HBV S gene to
inhibit HBV replication in HepG2.2.15 cells. It provided a good
model to study the effect of HBV load on HCC cells.
To study the effect of HBV replication on the migration of HCC
cells, we compared the invasive and metastatic potential of
HepG2.2.15 cells to cells transfected with HBV siRNAs. The results
indicated that HCC cells showed increased migratory ability when
HBV replication was inhibited by siRNA. Increasing evidence
suggests that EMT plays a critical role in the dissemination of
cancer cells during HCC progression,21,22 implicating a potential
mechanism. EMT is a reversible process by which epithelial cells
undergo a phenotypic conversion and assume a mesenchymal
cellular phenotype, including elongated morphology, enhanced
migratory and invasive ability, decreased expression of epithelial
markers (such as E-cadherin and b-catenin), and increased
expression of mesenchymal components (such as vimentin and
ﬁbronectin).23,24 Many factors can contribute to the invasion and
metastasis of HCC by inducing EMT processes, including hypoxia,
microRNAs, and some protein molecules.25–27 The tumor micro-
environment in HCC has been identiﬁed as one of the most potent
inducers of EMT and its reverse process mesenchymal–epithelial
transition (MET).28 In HBV-associated HCC, FAT10 has been found
to induce EMT and promote invasion of cancer cells.29 Suppression
of E-cadherin is at the center of the EMT process.30,31 E-cadherin is
the major mediator of cell adhesion in adherent junctions.
Translation factors, including Snail, Twist, and Zeb1, can regulate
the expression of E-cadherin by binding the E-box sequence in the
promoter region of CDH1.24
In this study, inhibition of HBV replication induced the
suppression of E-cadherin and turned on the expression ofransfected with siRNAs showed a relatively mesenchymal phenotype compared to
henotype.
Figure 3. Assay of invasive and metastatic ability. The cells in the siRNA1 and 2 groups demonstrated an augmented migration capacity when compared to blank control and
negative control (NC) cells. (a) Wound-healing assay. (b) The recovery ability of the cells to the wound-healing assay is represented as a percentage of the initial width. (c)
Trans-well assay. (d) The average number of migratory cells under a high power ﬁeld is demonstrated by the bar graph. Compared to HepG2.2.15 cells, *p < 0.01.
T. Wang et al. / International Journal of Infectious Diseases 20 (2014) 37–4140vimentin. The result of the Western blot assays conﬁrmed the
decreased expression of E-cadherin in HepG2.2.15 cells transfected
with siRNAs. Our previous study found that the parental cell line
HepG2 is more invasive than HepG2.2.15.8 This study veriﬁed aFigure 4. Immunoﬂuorescent staining. Inhibition of HBV replication suppressed the epit
vimentin.lower level of E-cadherin expression in HepG2 cells. Thus, HBV
replication might affect the migratory ability of host cells by
inducing the reverse process of EMT, especially the augmentation of
E-cadherin expression. Additionally, HepG2.2.15 cells transfectedhelial marker-E-cadherin and turned on the expression of the mesenchymal marker
Figure 5. Western blot assay. The level of E-cadherin in HepG2.2.15 and negative
control (NC) cells was higher compared to cells transfected with siRNA1 or 2
(p < 0.05). E-cadherin was signiﬁcantly increased in HepG2.2.15 cells compared to
HepG2 cells (p < 0.01).
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processes, which is consistent with a mesenchymal phenotype,
providing additional evidence for the presence of EMT.
In conclusion, the siRNA approach was effective at inhibiting
HBV replication. A high load of HBV replication inhibited the
invasive and metastatic ability of host cells by regulating EMT,
primarily by upregulating the expression of E-cadherin. Integra-
tion of the HBV whole genome might produce a different effect on
the migratory ability of host cells compared to the integration of a
part of the HBV gene. Additionally, this result may explain to some
extent why only a small percentage of patients with HBV infection
will progress to HBV-related HCC.
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